Bio

Bio


Dr. Rishi Raj is an Clinical Professor of Medicine at Stanford University and directs the Interstitial Lung Disease program at Stanford. He specializes in the diagnosis and treatment of interstitial lung diseases and has practiced pulmonary and critical care medicine for more than 15 years. Dr. Raj's primary clinical interest and primary focus of clinical research is interstitial lung diseases including idiopathic pulmonary fibrosis, other idiopathic interstitial lung diseases, drug induced interstitial lung diseases, interstitial lung disease associated with connective tissue diseases including scleroderma, rheumatoid arthritis, dermatomyositis etc., sarcoidosis, hypersensitivity pneumonitis and other miscellaneous interstitial lung diseases. Dr. Raj is the principal investigator and co-investigator on multiple clinical trials evaluating new therapies for treating idiopathic pulmonary fibrosis and pulmonary fibrosis/interstitial lung disease from other etiologies.

Clinical Focus


  • Idiopathic Pulmonary Fibrosis
  • Other Idiopathic Interstitial Lung Diseases
  • Connective Tissue Associated Interstitial Lung Disease (RA, Scleroderma, Myosites, others)
  • Drug Induced Interstitial Lung Diseases
  • Hypersensitivity Pneumonitis
  • Sarcoidosis
  • Other Interstitial Lung Diseases
  • Pulmonary Disease

Academic Appointments


Administrative Appointments


  • Director, Interstitial Lung Disease Program, Stanford (2017 - Present)

Professional Education


  • Board Certification: Critical Care Medicine, American Board of Internal Medicine (2003)
  • Board Certification: Pulmonary Disease, American Board of Internal Medicine (2002)
  • Fellowship:Baylor College of Medicine Registrar (2002) TX
  • Board Certification: Internal Medicine, American Board of Internal Medicine (1999)
  • Residency:Texas Tech University Health Sciences Center (1999) TX
  • Internship:Texas Tech University Health Sciences Center (1997) TX
  • Medical Education:Christian Medical College/Vellor (1995)

Publications

All Publications


  • Tissue Continues to Be the Issue Role of Histopathology in the Context of Recent Updates in the Radiologic Classification of Interstitial Lung Diseases ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE Raparia, K., Raj, R. 2019; 143 (1): 30–33
  • Rituximab Versus Mycophenolate Mofetil in Interstitial Lung Disease Secondary to Connective Tissue Disease Zhu, L., Li, S., Gagne, L., Jacobs, S., Morisset, J., Mooney, J., Raj, R., Chung, L. WILEY. 2018